Bromodomain inhibitors and uses thereof
AssigneeConstellation Pharmaceuticals, Inc.
InventorsBrian K. Albrecht, James E. Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael C. Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
Claims28
A compound of formula II-A:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is H, alkyl, aralkyl, aryl, heteroaryl, halo, ORA, NRARB, S(O)qRA, C(O)RA, C(O)ORA, OC(O)RA, or C(O)NRARB;
- each RA is independently optionally substituted alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted heterocyclic;
- optionally substituted carbocyclic;
- or hydrogen;
- each RB is independently optionally substituted alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted heterocyclic;
- optionally substituted carbocyclic;
- or hydrogen;
- Ring A is benzo;
- RC is a 3-7 membered saturated, partially unsaturated or completely unsaturated carbocyclic ring;
- a 3-7 membered aryl ring;
- or a 3-7 membered saturated, partially unsaturated, or completely unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RC is optionally substituted with 1-5 independently selected R4;
- R2 and R3 are each independently H, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, —OR, —SR, —CN, —N(R′)(R″), —C(O)R, —C(S)R, —CO2R, C(O)N(R′)(R″), —C(O)SR, or —(CH2)pRx;
- or
- R2 and R3 together with the atoms to which each is attached, forms an optionally substituted 3-7 membered saturated or partially unsaturated spiro-fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each Rx is independently halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, —OR, —SR, —CN, —N(R′)(R″), —C(O)R, —C(S)R, —CO2R, —C(O)N(R′)(R″), —C(O)SR, —C(O)C(O)R, —C(O)CH2C(O)R, —C(S)N(R′)(R″), —C(S)OR, —S(O)R, —SO2R, —SO2N(R′)(R″), —N(R′)C(O)R, —N(R′)C(O)N(R′)(R″), —N(R′)C(S)N(R′)(R″), —N(R′)SO2R, —N(R′)SO2N(R′)(R″), —N(R′)N(R′)(R″), —N(R′)C(═N(R′))N(R′)(R″), —C═NN(R′)(R″), —C═NOR, —C(═N(R′))N(R′)(R″), —OC(O)R, —OC(O)N(R′)(R″);
- each R is independently hydrogen, C1-6 aliphatic, a 5-6 membered aryl ring, a 3-7 membered saturated, partially unsaturated, or completely unsaturated carbocyclic ring, a 7-12 membered bicyclic saturated, partially unsaturated, or completely unsaturated carbocyclic ring, a 3-7 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-7 membered saturated, partially unsaturated, or completely unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered bicyclic saturated, partially unsaturated, or completely unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 7-12 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- each of which is optionally substituted;
- each R′ is independently —R, —C(O)R, —C(S)R, —CO2R, —C(O)N(R)2, —C(S)N(R)2, —S(O)R, —SO2R, —SO2N(R)2, or two R on the same nitrogen are taken together with their intervening atoms to form a 3-7 membered monocyclic saturated, partially unsaturated, or completely unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 7-12 membered bicyclic saturated, partially unsaturated, or completely unsaturated fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 3-7 membered monocyclic heteroaryl ring;
- or a 7-12 membered bicyclic heteroaryl;
- each of which is optionally substituted;
- each R″ is independently —R, —C(O)R, —C(S)R, —CO2R, —C(O)N(R)2, —C(S)N(R)2, —S(O)R, —SO2R, —SO2N(R)2, or two R on the same nitrogen are taken together with their intervening atoms to form a 3-7 membered monocyclic saturated, partially unsaturated, or completely unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 7-12 membered bicyclic saturated, partially unsaturated, or completely unsaturated fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 3-7 membered monocyclic heteroaryl ring;
- or a 7-12 membered bicyclic heteroaryl;
- each of which is optionally substituted;
- or
- R′ and R″, together with the atoms to which each is attached, can form a 3-7 membered monocyclic saturated, partially unsaturated, or completely unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 7-12 membered bicyclic saturated, partially unsaturated, or completely unsaturated fused heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- a 3-7 membered monocyclic heteroaryl ring;
- or a 7-12 membered bicyclic heteroaryl;
- each of which is optionally substituted;
- each R4 is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl, halogen, —OR, —SR, —N(R′)(R″), —CN, —NO2, —C(O)R, —C(S)R, —CO2R, —C(O)N(R′)(R″), —C(O)SR, —C(O)C(O)R, —C(O)CH2C(O)R, —C(S)N(R′)(R″), —C(S)OR, —S(O)R, —SO2R, —SO2N(R′)(R″), —N(R′)C(O)R, —N(R′)C(O)N(R′)(R″), —N(R′)C(S)N(R′)(R″), —N(R′)SO2R, —N(R′)SO2N(R′)(R″), —N(R′)N(R′)(R″), —N(R′)C(═N(R′))N(R′)(R″), —C═NN(R′)(R″), —C═NOR, —C(═N(R′))N(R′)(R″), —OC(O)R, or —OC(O)N(R′)(R″);
- each R5 is independently —R, halogen, —OR, —SR, —N(R′)(R″), —CN, or —NO2;
- n is 0-5;
- q is 0, 1, or 2;
- and
- p is 1-6.
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
A compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
A compound represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.